ABSTRACT
Abromo-substituted pyrazoline, 5-(2-bromophenyl)-3-(naphthalen-1-yl)-4,5-dihydro-1H-pyrazole (Compound 2), has been synthesized under microwave irradiation. The reaction occurred in a short time with a yield of 82%. The structure of this compound was characterized on the basis of spectroscopic data, including Ultraviolet–Visible (UV-Vis), Fourier-Transform Infrared (FTIR) spectroscopy, High-Resolution Mass Spectrometry (HRMS), and 1H and 13C Nuclear Magnetic Resonance (NMR). According to an in vivo anti-diabetic assay, the oral administration of Compound 2 in dosages of 25, 50 and 100 mg/kg of body weight showed significant (p < 0.05) increasing percentage changes in blood glucose level and weight of treated diabetic mice, compared to the negative control. Then, as an anti-diabetic drug, the oral administration of Compound 2 at a dosage of 100 mg/kg of body weight did not show a significant difference (p > 0.05) in the ability to reduce blood glucose level and prevent weight loss of diabetic mice in comparison to the use of glibenclamide. In addition, the oral administration of Compound 2 at dosages of 25, 50 and 100 mg/kg body weight did not show a significant (p > 0.05) effect on the relative weight of organs of treated diabetic mice compared to the normal control.
